Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2

AAPS Journal

Volumn 11, Issue 3, 2009, Pages 481-494

  Zhou, Shu Feng ^a   Yang, Li Ping ^b   Zhou, Zhi Wei ^a   Liu, Ya He ^a   Chan, Eli ^c  

^a RMIT UNIVERSITY   (Australia)

^b BEIJING HOSPITAL   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

CYP1A2; Inducer; Inhibitor; Single nuclear polymorphism; Substrate

Indexed keywords

ALBENDAZOLE; ALOSETRON; AMIODARONE; AROMATIC HYDROCARBON RECEPTOR; BUFURALOL; CAFFEINE; CARBAMAZEPINE; COUMARIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DULOXETINE; EFAVIRENZ; ERLOTINIB; ESTRADIOL; FLUTAMIDE; FLUVOXAMINE; GUANABENZ; HALOPERIDOL; IMATINIB; IMIPRAMINE; INDIPLON; LEFLUNOMIDE; LIDOCAINE; MAPROTILINE; MELATONIN; MEXILETINE; MIANSERIN; PHENACETIN; THEOPHYLLINE;

CRYSTAL STRUCTURE; DNA METHYLATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; EPIGENETICS; GENE FREQUENCY; HUMAN; HYDROXYLATION; LIGAND BINDING; MOLECULAR DOCKING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION;

ANIMALS; CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 73349108767     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9127-y     Document Type: Review

References (98)

1. J Corchero S Pimprale S Kimura FJ Gonzalez 2001 Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation Pharmacogenetics 11 1 6 11207026 10.1097/00008571-200102000-00001 1:CAS:528:DC%2BD3MXhtFKhurY%3D (Pubitemid 32108656)
2. K Ikeya AK Jaiswal RA Owens JE Jones DW Nebert S Kimura 1989 Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression Mol Endocrinol 3 1399 1408 2575218 10.1210/mend-3-9-1399 1:CAS:528:DyaK3cXhsFaku7Y%3D
3. AK Jaiswal DW Nebert OW McBride FJ Gonzalez 1987 Human P(3)450: cDNA and complete protein sequence, repetitive Alu sequences in the 3′ nontranslated region, and localization of gene to chromosome 15 J Exp Pathol 3 1 17 3681487 1:CAS:528:DyaL2sXktlCit7o%3D
4. T Shimada H Yamazaki M Mimura Y Inui FP Guengerich 1994 Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals J Pharmacol Exp Ther 270 414 423 8035341 1:CAS:528:DyaK2cXlt1OmtL4%3D
5. M Ingelman-Sundberg SC Sim A Gomez C Rodriguez-Antona 2007 Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 496 526 18001838 10.1016/j.pharmthera.2007.09.004 1:CAS:528:DC%2BD2sXhtlCrs7bE (Pubitemid 350116943)
6. SF Zhou YM Di E Chan, et al. 2008 Clinical pharmacogenetics and potential application in personalized medicine Curr Drug Metab 9 738 784 18855611 10.2174/138920008786049302 1:CAS:528:DC%2BD1cXhsVSitrrF
7. A Gunes ML Dahl 2008 Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms Pharmacogenomics 9 625 637 18466106 10.2217/14622416.9.5.625 1:CAS:528:DC%2BD1cXlvFyisr8%3D (Pubitemid 351803920)
8. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41:89-295.
9. DF Lewis BG Lake M Dickins YF Ueng PS Goldfarb 2003 Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure Xenobiotica 33 239 254 12637242 10.1080/0049825021000048791 1:CAS:528: DC%2BD3sXitVeku7o%3D (Pubitemid 36408193)
10. T Shimizu T Tateishi M Hatano Y Fujii-Kuriyama 1991 Probing the role of lysines and arginines in the catalytic function of cytochrome P450d by site-directed mutagenesis. Interaction with NADPH-cytochrome P450 reductase J Biol Chem 266 6 3372 3375 1899862 1:CAS:528:DyaK3MXhtlyktrY%3D
11. J Liu SS Ericksen M Sivaneri D Besspiata CW Fisher GD Szklarz 2004 The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism Arch Biochem Biophys 424 33 43 15019834 10.1016/j.abb.2003.12.040 1:CAS:528:DC%2BD2cXhvFSls70%3D (Pubitemid 38326852)
12. S Sansen JK Yano RL Reynald, et al. 2007 Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2 J Biol Chem 282 14348 14355 17311915 10.1074/jbc.M611692200 1:CAS:528: DC%2BD2sXkvVynsLc%3D (Pubitemid 47100434)
13. JK Yano MH Hsu KJ Griffin CD Stout EF Johnson 2005 Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen Nat Struct Mol Biol 12 822 823 16086027 10.1038/nsmb971 1:CAS:528: DC%2BD2MXpslaqt7Y%3D (Pubitemid 43086258)
14. MS Faber A Jetter U Fuhr 2005 Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97 125 134 16128905 10.1111/j.1742-7843.2005.pto-973160.x 1:CAS:528:DC%2BD2MXhtVejsb3L (Pubitemid 41291208)
15. R Yuan S Madani XX Wei K Reynolds SM Huang 2002 Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions Drug Metab Dispos 30 1311 1319 12433797 10.1124/dmd.30.12.1311 1:CAS:528:DC%2BD38XptVyisrY%3D (Pubitemid 35397032)
16. DJ Waxman TK Chang 2006 Use of 7-ethoxycoumarin to monitor multiple enzymes in the human CYP1, CYP2, and CYP3 families Methods Mol Biol 320 153 156 16719387 1:CAS:528:DC%2BD28XhtFyqsb0%3D
17. S Rendic 2002 Summary of information on human CYP enzymes: human P450 metabolism data Drug Metab Rev 34 83 448 11996015 10.1081/DMR-120001392 1:CAS:528:DC%2BD38Xjs1KgsLY%3D (Pubitemid 34311090)
18. SF Zhou HL Koh YH Gao ZY Gong EJD Lee 2004 Herbal bioactivation: the good, the bad and the ugly Life Sci 74 935 968 14672753 10.1016/j.lfs.2003.09. 035 1:CAS:528:DC%2BD3sXps1GqsL8%3D (Pubitemid 37522131)
19. YF Ueng CH Hsieh MJ Don CW Chi LK Ho 2004 Identification of the main human cytochrome P450 enzymes involved in safrole 1'-hydroxylation Chem Res Toxicol 17 1151 1156 15310247 10.1021/tx030055p 1:CAS:528:DC%2BD2cXmtVehsbg%3D (Pubitemid 39108682)
20. M Stiborova E Frei M Wiessler HH Schmeiser 2001 Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2 Chem Res Toxicol 14 1128 1137 11511187 10.1021/tx010059z 1:CAS:528:DC%2BD3MXltlSqt7s%3D (Pubitemid 32800169)
21. FP Guengerich T Shimada 1998 Activation of procarcinogens by human cytochrome P450 enzymes Mutat Res 400 201 213 9685642 1:CAS:528: DyaK1cXks1Onsrc%3D (Pubitemid 28440223)
22. CL Crespi BW Penman DT Steimel T Smith CS Yang TR Sutter 1997 Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens Mutagenesis 12 83 89 9106248 1:CAS:528:DyaK2sXisFOqtbc%3D
23. DJ Skene E Papagiannidou E Hashemi, et al. 2001 Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices J Pineal Res 31 333 342 11703563 10.1034/j.1600-079X.2001.310408.x 1:CAS:528:DC%2BD3MXotlCnt7k%3D (Pubitemid 33032949)
24. RW Lambrecht PR Sinclair N Gorman JF Sinclair 1992 Uroporphyrinogen oxidation catalyzed by reconstituted cytochrome P450 1A2 Arch Biochem Biophys 294 504 510 1567206 10.1016/0003-9861(92)90717-B 1:CAS:528:DyaK38XhvFSjtbs%3D
25. H Yamazaki PM Shaw FP Guengerich T Shimada 1998 Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes Chem Res Toxicol 11 659 665 9625734 10.1021/tx970217f 1:CAS:528: DyaK1cXjvFars7c%3D (Pubitemid 28285591)
26. Q Ma 2001 Induction of CYP1A1. The AhR/DRE paradigm: transcription, receptor regulation, and expanding biological roles Curr Drug Metab 2 149 164 11469723 10.2174/1389200013338603 1:CAS:528:DC%2BD3MXktlOgsL0%3D (Pubitemid 32537000)
27. Q Ma AY Lu 2007 CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies Drug Metab Dispos 35 1009 1016 17431034 10.1124/dmd.107.015826 1:CAS:528:DC%2BD2sXns1yiu7o%3D (Pubitemid 46956419)
28. JT Backman MT Granfors PJ Neuvonen 2006 Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine Eur J Clin Pharmacol 62 451 461 16758262 10.1007/s00228-006-0127-x 1:CAS:528:DC%2BD28XltlOjurg%3D (Pubitemid 43873717)
29. DW Nebert TP Dalton AB Okey FJ Gonzalez 2004 Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer J Biol Chem 279 23847 23850 15028720 10.1074/jbc.R400004200 1:CAS:528:DC%2BD2cXksV2jurY%3D (Pubitemid 38725238)
30. KM Burbach A Poland CA Bradfield 1992 Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor Proc Natl Acad Sci U S A 89 8185 8189 1325649 10.1073/pnas.89.17.8185 1:CAS:528:DyaK3sXkt1ejsrc%3D
31. LA Carver CA Bradfield 1997 Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo J Biol Chem 272 11452 11456 9111057 10.1074/jbc.272.17.11452 1:CAS:528:DyaK2sXjtVamu7g%3D (Pubitemid 27184153)
32. MF Yueh YH Huang A Hiller S Chen N Nguyen RH Tukey 2003 Involvement of the xenobiotic response element (XRE) in Ah receptor-mediated induction of human UDP-glucuronosyltransferase 1A1 J Biol Chem 278 15001 15006 12566446 10.1074/jbc.M300645200 1:CAS:528:DC%2BD3sXjtVClsro%3D (Pubitemid 36799832)
33. K Ohyama M Nakajima M Suzuki N Shimada H Yamazaki T Yokoi 2000 Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions Br J Clin Pharmacol 49 244 253 10718780 10.1046/j.1365-2125.2000.00134.x 1:CAS:528:DC%2BD3cXis1ehu7o%3D (Pubitemid 30150986)
34. Thelingwani RS, Zvada SP, Hugues D, Ungell AL, Masimirembwa CM. In vitro and in silico identification and characterisation of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. Drug Metab Dispos. 2009;37:1286-94.
35. Q Zhu J Liao L Xie GJ Wang XD Liu 2009 Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats Xenobiotica 39 293 301 19350452 10.1080/00498250802709428 1:CAS:528:DC%2BD1MXos1agurc%3D
36. S Langouet LL Furge N Kerriguy K Nakamura A Guillouzo FP Guengerich 2000 Inhibition of human cytochrome P450 enzymes by 1, 2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane Chem Res Toxicol 13 245 252 10775323 10.1021/tx990189w 1:CAS:528:DC%2BD3cXhvVyrtb4%3D (Pubitemid 30241650)
37. Chang TK, Chen J, Lee WB. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001;299:874-82.
38. T Shimada H Yamazaki M Foroozesh NE Hopkins WL Alworth FP Guengerich 1998 Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1 Chem Res Toxicol 11 1048 1056 9760279 10.1021/tx980090+ 1:CAS:528: DyaK1cXkvFCnt7c%3D (Pubitemid 28447294)
39. US Cho EY Park MS Dong BS Park K Kim KH Kim 2003 Tight-binding inhibition by α-naphthoflavone of human cytochrome P450 1A2 Biochim Biophys Acta 1648 195 202 12758162 1:CAS:528:DC%2BD3sXjvFWmu7Y%3D (Pubitemid 38234621)
40. KG Jensen HE Poulsen J Doehmer S Loft 1995 Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2 Pharmacol Toxicol 76 286 288 7617560 10.1111/j.1600-0773.1995.tb00144.x 1:STN:280:DyaK2Mzkt1Ortw%3D%3D
41. BB Rasmussen J Maenpaa O Pelkonen, et al. 1995 Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine Br J Clin Pharmacol 39 151 159 7742153 1:CAS:528:DyaK2MXltlGhsro%3D
42. AC Parker T Preston D Heaf NR Kitteringham I Choonara 1994 Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test Br J Clin Pharmacol 38 573 576 7888295 1:STN:280:DyaK2M7psVyjtA%3D%3D
43. MT Granfors JT Backman M Neuvonen PJ Neuvonen 2004 Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism Clin Pharmacol Ther 76 598 606 15592331 10.1016/j.clpt.2004.08.018 1:CAS:528:DC%2BD2cXhtVKlt7vO (Pubitemid 39601549)
44. L Zhang MJ Wei CY Zhao HM Qi 2008 Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes Acta Pharmacol Sin 29 1507 1514 19026171 10.1111/j.1745-7254.2008.00908.x 1:CAS:528:DC%2BD1MXisF2jsQ%3D%3D
45. YF Ueng WC Jan LC Lin TL Chen FP Guengerich CF Chen 2002 The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes Drug Metab Dispos 30 349 353 11854157 10.1124/dmd.30.3.349 1:CAS:528:DC%2BD38Xhtl2qtL0%3D (Pubitemid 34175029)
46. F Qiu R Zhang J Sun, et al. 2008 Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes Drug Metab Dispos 36 1308 1314 18411400 10.1124/dmd.108.021030 1:CAS:528:DC%2BD1cXotVegu7s%3D (Pubitemid 351929315)
47. HC Liang H Li RA McKinnon, et al. 1996 CYP1A2(-/-) null mutant mice develop normally but show deficient drug metabolism Proc Natl Acad Sci U S A 93 1671 1676 8643688 10.1073/pnas.93.4.1671 1:CAS:528:DyaK28Xht1ent7c%3D (Pubitemid 26075183)
48. -/- null mutant mice Biochem Pharmacol 54 1127 1131 9464455 10.1016/S0006-2952(97)00263-3 1:CAS:528:DyaK2sXntFemtbw%3D (Pubitemid 27479026)
49. JM Lasker MT Huang AH Conney 1982 In vivo activation of zoxazolamine metabolism by flavone Science 216 1419 1421 7089530 10.1126/science.7089530 1:CAS:528:DyaL38XksV2huro%3D
50. JT Buters BK Tang T Pineau HV Gelboin S Kimura FJ Gonzalez 1996 Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2 Pharmacogenetics 6 291 296 8873215 10.1097/00008571-199608000-00002 1:CAS:528:DyaK28XlvFaqtrg%3D
51. +/+ mice J Natl Cancer Inst 95 1227 1237 12928348 1:CAS:528:DC%2BD3sXntlWqsbw%3D
52. AG Smith R Davies TP Dalton, et al. 2003 Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse EHP Toxicogenomics 111 45 51 12735109 1:CAS:528: DC%2BD3sXhtlOisL0%3D
53. MA Kall J Clausen 1995 Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man Hum Exp Toxicol 14 801 807 8562120 10.1177/096032719501401004 1:CAS:528:DyaK2MXpslSltLc%3D
54. MV Relling JS Lin GD Ayers WE Evans 1992 Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities Clin Pharmacol Ther 52 643 658 1458773 1:CAS:528:DyaK3sXhtFKitLk%3D
55. BB Rasmussen TH Brix KO Kyvik K Brosen 2002 The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors Pharmacogenetics 12 473 478 12172216 10.1097/00008571-200208000-00008 1:CAS:528:DC%2BD38XmslejtLk%3D (Pubitemid 34913530)
56. KJ Aitchison FJ Gonzalez LC Quattrochi, et al. 2000 Identification of novel polymorphisms in the 5′ flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance Pharmacogenetics 10 695 704 11186132 10.1097/00008571-200011000-00004 1:CAS:528:DC%2BD3cXovF2qs7Y%3D
57. A Soyama Y Saito N Hanioka, et al. 2005 Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population Drug Metab Pharmacokinet 20 24 33 15770072 10.2133/dmpk.20.24 1:CAS:528:DC%2BD2MXhtFSrsL3N
58. M Chida T Yokoi T Fukui M Kinoshita J Yokota T Kamataki 1999 Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population Jpn J Cancer Res 90 899 902 10551315 1:CAS:528:DyaK1MXntlGgsb0%3D
59. M Nakajima T Yokoi M Mizutani M Kinoshita M Funayama T Kamataki 1999 Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans J Biochem 125 803 808 10101295 1:CAS:528:DyaK1MXjsVyrtbg%3D
60. C Sachse J Brockmoller S Bauer I Roots 1999 Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine Br J Clin Pharmacol 47 445 449 10233211 10.1046/j.1365-2125.1999. 00898.x 1:CAS:528:DyaK1MXivVCmtLo%3D (Pubitemid 29161279)
61. R Ghotbi M Christensen HK Roh M Ingelman-Sundberg E Aklillu L Bertilsson 2007 Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans Eur J Clin Pharmacol 63 537 546 17370067 10.1007/s00228-007-0288-2 1:CAS:528:DC%2BD2sXkslWns70%3D (Pubitemid 46684487)
62. XM Han DS Ouyang XP Chen, et al. 2002 Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2 Br J Clin Pharmacol 54 540 543 12445035 10.1046/j.1365-2125.2002.01686.x 1:CAS:528:DC%2BD38Xps1Olsbk%3D (Pubitemid 35356882)
63. E Aklillu JA Carrillo E Makonnen, et al. 2003 Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 Mol Pharmacol 64 659 669 12920202 10.1124/mol.64.3.659 1:CAS:528:DC%2BD3sXmvFahsr8%3D (Pubitemid 37048569)
64. JD Huang WC Guo MD Lai YL Guo GH Lambert 1999 Detection of a novel cytochrome P450 1A2 polymorphism (F21L) in Chinese Drug Metab Dispos 27 98 101 9884316 1:CAS:528:DyaK1MXktFylug%3D%3D
65. C Sachse U Bhambra G Smith, et al. 2003 Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism Br J Clin Pharmacol 55 68 76 12534642 10.1046/j.1365-2125.2003.01733.x 1:CAS:528:DC%2BD3sXhsFOkur0%3D (Pubitemid 36110841)
66. L Pucci A Geppetti V Maggini D Lucchesi A Maria Rossi V Longo 2007 CYP1A2 F21L and F186L polymorphisms in an Italian population sample Drug Metab Pharmacokinet 22 220 222 17603224 10.2133/dmpk.22.220
67. D Chevalier C Cauffiez D Allorge, et al. 2001 Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population Hum Mutat 17 355 356
68. T Bilgen O Tosun G Luleci I Keser 2008 Frequencies of four genetic polymorphisms in the CYP1A2 gene in Turkish population Genetika 44 1133 1136 18825963 1:STN:280:DC%2BD1cnjsFyjtg%3D%3D
69. SI Hamdy M Hiratsuka K Narahara, et al. 2003 Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population Br J Clin Pharmacol 55 321 324 12630986 10.1046/j.1365-2125.2003.01787.x 1:CAS:528: DC%2BD3sXjsFyltr8%3D (Pubitemid 36390765)
70. C Skarke A Kirchhof G Geisslinger J Lotsch 2005 Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing Eur J Clin Pharmacol 61 887 892 16307269 10.1007/s00228-005-0029-3 1:CAS:528:DC%2BD2MXhtlajsrvN (Pubitemid 41803698)
71. Y Obase T Shimoda T Kawano, et al. 2003 Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma Clin Pharmacol Ther 73 468 474 12732846 10.1016/S0009-9236(03)00013-4 1:CAS:528:DC%2BD3sXjsVGmtLs%3D (Pubitemid 36549830)
72. CB Eap S Bender E Jaquenoud Sirot, et al. 2004 Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene J Clin Psychopharmacol 24 214 219 15206669 10.1097/01.jcp.0000116646.91923.2f 1:CAS:528:DC%2BD2cXjslSit7k%3D (Pubitemid 38380846)
73. V Ozdemir W Kalow AB Okey, et al. 2001 Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C>A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine J Clin Psychopharmacol 21 603 607 11763009 10.1097/00004714-200112000-00011 1:CAS:528:DC%2BD38XisFehtg%3D%3D (Pubitemid 33116661)
74. KI Melkersson MG Scordo A Gunes ML Dahl 2007 Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients J Clin Psychiatry 68 697 704 17503978 1:CAS:528:DC%2BD2sXmslKmtLs%3D
75. R Berecz A de la Rubia P Dorado P Fernandez-Salguero ML Dahl A Llerena 2003 Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype Eur J Clin Pharmacol 59 45 50 12682803 1:CAS:528:DC%2BD3sXjslWhsLo%3D
76. K Mihara T Kondo A Suzuki, et al. 2001 Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients Pharmacol Toxicol 88 267 270 11393588 10.1034/j.1600-0773.2001.d01-115.x 1:CAS:528:DC%2BD3MXktVWmtbg%3D
77. S Hartter T Korhonen S Lundgren, et al. 2006 Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin Basic Clin Pharmacol Toxicol 99 300 304 17040215 10.1111/j.1742-7843.2006.pto-491.x (Pubitemid 44578906)
78. P Bohanec Grabar B Rozman M Tomsic D Suput D Logar V Dolzan 2008 Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients Eur J Clin Pharmacol 64 9 871 876 18496682 10.1007/s00228-008-0498-2 1:CAS:528:DC%2BD1cXhtVKju7bO
79. DF Lewis BG Lake 1996 Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues Xenobiotica 26 723 753 8819302 10.3109/00498259609046745 1:CAS:528:DyaK28Xkt1Cks7s%3D
80. H Mayuzumi C Sambongi K Hiroya T Shimizu T Tateishi M Hatano 1993 Effect of mutations of ionic amino acids of cytochrome P450 1A2 on catalytic activities toward 7-ethoxycoumarin and methanol Biochemistry 32 5622 5628 8504082 10.1021/bi00072a018 1:CAS:528:DyaK3sXksVCitLg%3D
81. R Dai S Zhai X Wei MR Pincus RE Vestal FK Friedman 1998 Inhibition of human cytochrome P450 1A2 by flavone: a molecular modeling study J Protein Chem 17 643 650 9853678 10.1007/BF02780965 1:CAS:528:DyaK1cXnvVCmtLo%3D
82. NE Hadjokas R Dai FK Friedman, et al. 2002 Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxyresorufin metabolism in lymphoblastoid cells Br J Pharmacol 136 347 352 12023936 10.1038/sj.bjp.0704711 1:CAS:528:DC%2BD38Xks1KqtLc%3D
83. JJ Lozano M Pastor G Cruciani, et al. 2000 3D-QSAR methods on the basis of ligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands J Comput Aided Mol Des 14 341 353 10815771 10.1023/A:1008164621650 1:CAS:528:DC%2BD3cXjt1GrtLw%3D (Pubitemid 30219396)
84. A Parikh PD Josephy FP Guengerich 1999 Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties Biochemistry 38 5283 5289 10220313 10.1021/bi990142+ 1:CAS:528:DyaK1MXitFGqtbc%3D (Pubitemid 29211211)
85. 5 Arch Biochem Biophys 310 367 372 8179321 10.1006/abbi.1994.1180 1:CAS:528:DyaK2cXkslOjur8%3D (Pubitemid 24172680)
86. T Cvrk HW Strobel 1998 Photoaffinity labeling of cytochrome P4501A1 with azidocumene: identification of cumene hydroperoxide binding region Arch Biochem Biophys 349 95 104 9439587 10.1006/abbi.1997.0464 1:CAS:528:DyaK1cXjtVKgsA%3D%3D (Pubitemid 28368395)
87. AG Krainev T Shimizu K Hiroya M Hatano 1992 Effect of mutations at Lys250, Arg251, and Lys253 of cytochrome P450 1A2 on the catalytic activities and the bindings of bifunctional axial ligands Arch Biochem Biophys 298 198 203 1524428 10.1016/0003-9861(92)90113-B 1:CAS:528:DyaK3sXns1Shtw%3D%3D
88. T Shimizu Y Murakami M Hatano 1994 Glu318 and Thr319 mutations of cytochrome P450 1A2 remarkably enhance homolytic O-O cleavage of alkyl hydroperoxides. An optical absorption spectral study J Biol Chem 269 13296 13304 7909807 1:CAS:528:DyaK2cXksFaqtrc%3D
89. T Shimizu O Ito M Hatano Y Fujii-Kuriyama 1991 CO binding studies of engineered cytochrome P450ds: effects of mutations at putative distal sites in the presence of polycyclic hydrocarbons Biochemistry 30 4659 4662 2029514 10.1021/bi00233a004 1:CAS:528:DyaK3MXit1ehurg%3D
90. AG Krainev T Shimizu M Ishigooka K Hiroya M Hatano Y Fujii-Kuriyama 1991 Absorption spectral study of cytochrome P450d-phenyl isocyanide complexes: effects of mutations at the putative distal site on the conformational stability Biochemistry 30 11206 11211 1958658 10.1021/bi00111a003 1:CAS:528: DyaK3MXmslektrc%3D
91. K Hiroya Y Murakami T Shimizu M Hatano Ortiz de Montellano PR 1994 Differential roles of Glu318 and Thr319 in cytochrome P450 1A2 catalysis supported by NADPH-cytochrome P450 reductase and tert-butyl hydroperoxide Arch Biochem Biophys 310 397 401 7910007 10.1006/abbi.1994.1184 1:CAS:528: DyaK2cXkslOjurw%3D (Pubitemid 24172684)
92. R Nakano H Sato A Watanabe O Ito T Shimizu 1996 Conserved Glu318 at the cytochrome P450 1A2 distal site is crucial in the nitric oxide complex stability J Biol Chem 271 8570 8574 8621484 10.1074/jbc.271.15.8570 1:CAS:528: DyaK28Xitlensrw%3D (Pubitemid 26123272)
93. S Pavanello A Pulliero S Lupi P Gregorio E Clonfero 2005 Influence of the genetic polymorphism in the 5′-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers Mutat Res 587 59 66 16188490 1:CAS:528:DC%2BD2MXhtFKms7%2FE
94. A Nordmark S Lundgren B Ask F Granath A Rane 2002 The effect of the CYP1A2*1F mutation on CYP1A2 inducibility in pregnant women Br J Clin Pharmacol 54 504 510 12445029 10.1046/j.1365-2125.2002.01673.x 1:CAS:528:DC%2BD38Xps1Olsb0%3D (Pubitemid 35356876)
95. X Chen L Wang L Zhi, et al. 2005 The G-3113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population Clin Pharmacol Ther 78 249 259 16153396 10.1016/j.clpt.2005.05.012 1:CAS:528:DC%2BD2MXpvV2rt74%3D (Pubitemid 41254110)
96. XM Han DS Ou-Yang PX Lu, et al. 2001 Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2 Pharmacogenetics 11 429 435 11470995 10.1097/00008571-200107000-00006 1:CAS:528:DC%2BD3MXlvVynsbc%3D (Pubitemid 32656583)
97. C Dandara PT Basvi TE Bapiro J Sayi JA Hasler 2004 Frequency of -163 C>A and 63 C>G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations Clin Chem Lab Med 42 939 941 15387446 10.1515/CCLM.2004.152 1:CAS:528:DC%2BD2cXns1Shurg%3D (Pubitemid 39206333)
98. F B'Chir S Pavanello J Knani S Boughattas MJ Arnaud S Saguem 2009 CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population Life Sci 84 21-22 779 784 19332078 10.1016/j.lfs.2009.03.008 1:CAS:528:DC%2BD1MXls1Khtbg%3D